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Submacular hemorrhage (SMH) is a rare but devastating 
complication of neovascular age-related macular degenera-
tion (AMD) [1]. The overall annual incidence of SMH among 
patients with exudative AMD has been estimated at 0.14% 
[2]. Damage to the sensory retina and the RPE by SMH has 
been attributed to limited nutrient diffusion from the choroid 
toward the retina, the shrinkage of the outer retinal layers due 
to clot formation, and the accumulation of toxic substances, 
such as fibrin and iron [3,4].
Recombinant tissue plasminogen activator (rtPA) is 
a serine protease of 70 kDa that, in the presence of fibrin, 
catalyzes the conversion of plasminogen to plasmin, breaking 
down the fibrin clot into degradation products [5-7]. Intrave-
nous rtPA is approved for coronary and cerebral thrombolysis 
in myocardial infarction and ischemic stroke, respectively. 
Off-label rtPA is currently used in ophthalmology to perform 
fibrinolysis in SMH [8]. The vitreoretinal procedure consists 
of either intravitreal or subretinal injections of rtPA, followed 
by gas tamponade meant to displace the dissolved blood 
collection [9-15]. The two routes showed similar efficacy 
regarding hematoma displacement and similar complica-
tion rates [16]. However, the exact visual benefits of the 
procedure cannot be ascertained: Although rtPA efficiently 
contributes to dissolving the fibrin clot, rtPA may induce 
neuronal damage [17-19]. In the central nervous system, 
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Purpose: Intravitreal recombinant tissue plasminogen activator (rtPA) is used off-label for the surgical management of 
submacular hemorrhage, a severe complication of neovascular age-related macular degeneration. rtPA is approved for 
coronary and cerebral thrombolysis. However, in ischemic stroke rtPA is known to increase excitotoxic neural cell death 
by interacting with the N-methyl-D-aspartate (NMDA) receptor. We therefore investigated the retinal toxicity of rtPA 
in healthy rats and in a model of NMDA-induced retinal excitotoxicity.
Methods: First, rtPA at three different doses (2.16 µg/5 µl, 0.54 µg/5 µl, and 0.27 µg/5 µl) or vehicle (NaCl 0.9%) was 
injected intravitreally in healthy rat eyes. Electroretinograms (ERGs) were performed at 24 h or 7 days. Annexin V-
fluorescein isothiocyanate (FITC)-labeled apoptotic retinal ganglion cells (RGCs) were counted on flatmounted retinas at 
24 h or 7 days. Next, NMDA + vehicle or NMDA + rtPA (0.27 µg/5 µl) was injected intravitreally to generate excitotoxic 
conditions. Apoptotic annexin V-FITC-labeled RGCs and surviving Brn3a-labeled RGCs were quantified on flatmounted 
retinas and radial sections, 18 h after treatment.
Results: In healthy rat eyes, the number of apoptotic RGCs was statistically significantly increased 24 h after the 
administration of rtPA at the highest dose (2.16 µg/5 µl; p = 0.0250) but not at the lower doses of 0.54 and 0.27 µg/5 µl 
(p = 0.36 and p = 0.20), compared to vehicle. At day 7, there was no difference in the apoptotic RGC count between the 
rtPA- and vehicle-injected eyes (p = 0.70, p = 0.52, p = 0.11). ERG amplitudes and implicit times were not modified at 
24 h or 7 days after injection of any tested rtPA doses, compared to the baseline. Intravitreal administration of NMDA 
induced RGC death, but under these excitotoxic conditions, coadministration of rtPA did not increase the number of 
dead RGCs (p = 0.70). Similarly, the number of surviving RGCs on the flatmounted retinas and retinal sections did not 
differ between the eyes injected with NMDA + vehicle and NMDA + rtPA (p = 0.59 and p = 0.67).
Conclusions: At low clinical equivalent doses corresponding to 25 µg/0.1 ml in humans, intravitreal rtPA is not toxic for 
healthy rat retinas and does not enhance NMDA-induced excitotoxicity. Vitreal equivalent doses ≥200 µg/0.1 ml should 
be avoided in patients, due to potential RGC toxicity.
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tissue plasminogen activator (tPA) can potentiate excitotoxic 
neuronal death [20], via the N-methyl-D-aspartate receptor 
(NMDAR), inducing calcium influx and activation of extra-
cellular signal regulated kinases 1/2 (ERK 1/2) with subse-
quent neuronal death [21-24]. However, at low concentrations, 
tPA can activate NMDAR via a plasminogen-independent 
mechanism, turning on the ERK 1/2-CREB-Atf3 prosurvival 
pathway that protects neurons from excitotoxicity [25-27]. 
Depending on the excitotoxic conditions and concentration, 
rtPA thus may be either pro- or antiapoptotic. In ophthal-
mology, there is no consensus regarding the appropriate dose 
of rtPA administered, which varies from 10 to 100 µg/0.1 ml.
Retinal safety studies in healthy rabbits and cats did 
not show toxicity when rtPA was injected intravitreally at 
a concentration of 25 µg/0.1 ml [28-30]. However, whether 
non-toxic concentrations remain safe under retinal excitotoxic 
conditions mimicking SMH remains to be determined. As 
retinal ganglion cells (RGCs) display N-methyl-D-aspartate 
(NMDA)-dependent neurotoxicity [17,18,31-35], we investi-
gated the retinal toxicity of rtPA in healthy rats and in a rat 
model of NMDA-induced retinal excitotoxicity.
METHODS
The experimental flowchart is provided in Appendix 1.
Animals: Forty-two male Long Evans rats (Elevage Janvier, 
Le Genest Saint-Isle, France; age: 6 weeks) were handled in 
accordance with the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research. Animal experiments 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Paris Descartes University 
(Paris, France, reference: 00377.01). Rats were anesthetized 
by intramuscular injection of 100 µl/100 g of a solution 
containing ketamine (40 mg/ml; Ketamine 1,000®, Virbac, 
Carros, France) and xylazine (4 mg/ml; Rompun 2%®, Bayer 
Santé, Puteaux, France). Pupillary dilatation was obtained by 
instillation of 2 drops of tropicamide (Mydriaticum 0.5%®, 
Thea, France) with a 5-min interval. Topical ocular anes-
thesia with 1 drop of tetracaine chlorohydrate (Tetracaine 
1%®, Faure, France) was performed 2 min before injection. 
Animals were euthanazied by an overdose (150 mg/kg) of 
intraperitoneal pentobarbital and eyes enucleated for analysis.
Tested compounds: Intravitreal injections were performed 
on anesthetized rats after pupillary dilatation as described. 
Animals were installed on an operating table with a surgical 
eye drape. Under microscope visualization, injections were 
performed into the vitreous in the inferior quadrant of the eye, 
using 300-µl sterile syringes fitted with 30-Gauge needles 
(Microfine©, Becton Dickinson AG, Meylan, France). A 
lubricant eye gel (Lacrigel®, Europhta, Monaco) was admin-
istered at the end of the procedure.
First, we analyzed the potential toxicity of increasing 
doses of intravitreal rtPA in healthy rats (n = 24 animals), 
assessed at 24 h and 7 days. Five microliters of solution 
containing 0.27, 0.54, or 2.16 µg rtPA (Actilyse® 10 mg, 
Boehringer-Ingelheim, Germany) were injected into the 
vitreous (n = 6 eyes per dose and per time point). Control 
eyes received 5 µl of saline solution (NaCl 0.9%, n = 6 eyes 
per time point), which is employed clinically to resuspend 
rtPA before administration, and served as the vehicle for the 
treated eye in the present experiment. The three doses of 
intravitreal rtPA selected for this experiment were calculated 
by analogy with the doses used clinically. A literature survey 
indicated that 25 to 50 µg/0.1 ml of rtPA is the most common 
Figure 1. Number of apoptotic 
retinal ganglion cells in f lat-
mounted healthy retinas 24 h after 
intravitreal administration of rtPA 
(2.16, 0.54, and 0.27 µg in 5 µl) or 
vehicle (NaCl 0.9%, 5 µl). There 
was a statistically significantly 
higher number of apoptotic cells in 
the eyes that received 2.16 µg/5 µl 
compared to vehicle. * p<0.05.
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dose injected into the vitreous [16]. Given the average eyeball 
volume of Long Evans rats (0.05 ml) [36], the equivalent 
doses resulting in similar vitreal concentrations in rats are 
0.27 and 0.54 µg/5 µl, respectively. We also tested a dose of 
2.16 µg/5 µl (4 × 0.54 µg) to estimate the toxicity threshold.
Then, we evaluated the potential additive toxicity of rtPA 
in NMDA-induced excitotoxic conditions (n = 18 animals). 
For this experiment, the lowest clinical equivalent dose of 
rtPA (0.27 µg/5 µl) was selected to assess its safety. Intravit-
real injection of 45 nmol of NMDA (Sigma, Poole, UK) in 
6 µl of 1× Dubelcco's phosphate-buffered saline (PBS; 1X; 
138 mM NaCl, 2.7 mM KCl, 8 mM NaPO4, 1.5 mM KPO4, 
pH 7.0-7.3) was performed to induce RGC death at 18 h, as 
previously described [37,38],, with (n = 18 eyes) or without (n 
= 18 eyes) intravitreal rtPA coadministration at the time of 
NMDA injection.
Assessment of rtPA-induced retinal toxicity:
Electroretinography—Electroretinograms (ERGs) 
were performed before and 24 h and 7 days after the rtPA 
injections. Full-field ERGs were performed on anesthetized 
rats (Rats were anesthetized by intramuscular injection of 
100µl/100 g of a solution containing ketamine (40 mg/ml; 
Ketamine 1,000®, Virbac, Carros, France) and xylazine (4 
mg/ml; Rompun 2%®, Bayer Santé, Puteaux, France). Topical 
ocular anesthesia with 1 drop of tetracaine chlorhydrate 
(Tetracaine 1%®, Faure, France) was performed 2 min prior 
to injection under dim red light. Gold wire ring electrodes 
were placed on the corneas and inserted into the forehead, 
and served as the working and reference electrodes, respec-
tively. A stainless steel needle electrode was subcutaneously 
inserted at the base of the animal tail for grounding. Measure-
ments were performed using the commercial VisioSystem 
Figure 2. Flatmounted retinas from 
rats euthanized 24 h after intravit-
real administration of rtPA (2.16 
µg/5 µl) or vehicle (NaCl 0.9%, 5 
µl). Apoptotic retinal ganglion cells 
labeled with intravitreal annexin 
V-f luorescein isothiocyanate 
(FITC) (A–C) or annexin V-FITC 
and 4',6-diamidino-2-phenylindole 
(DAPI) (B–D) before the animals 
were euthanized. A, B: Control eye 
(NaCl 0.9%, 5 µl). C, D: Eye treated 
with intravitreal recombinant tissue 
plasminogen activator (rtPA; 2.16 
µg/5 µl) displaying a higher number 
of annexin V-FITC labeling, colo-
calizing with retinal ganglion cell 
nuclei. Green = Annexin-V-FITC 
staining; Blue = DAPI staining. Bar 
= 50 µm.
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device (Siem Biomedicale, Nîmes, France). For the scotopic 
recordings, animals were dark-adapted overnight. Flash 
intensities ranged from 0.0003 to 10 cd.s/m2. Five flashes 
per stimulation intensity were applied at a 0.5 Hz frequency, 
under scotopic conditions, and the corresponding responses 
were averaged. The flash duration was 10 ms (–30 to 0 dB) 
except for 10 cd.s/m2, which was 30 ms (0 dB). For the phot-
opic recordings, the animals were light-adapted for 5 min 
with a rod-suppressing background light of 25 cd/m2. A light 
flash was then applied, and the light intensity was 10 cd.s/m2 
(flash duration 79 ms). The amplitudes (in μV) and latencies 
(in ms) of the a- and b-waves were measured. For each eye, 
we calculated the variation (the difference between the post-
treatment and pretreatment values) of each ERG parameter 
(amplitudes, implicit times). Data obtained from all eyes in 
the same experimental group were averaged, and the treat-
ment groups were compared.
Quantification of apoptotic cells—The apoptotic 
cells were labeled in vivo with an intravitreal injection of 
2 μg/10 µl of annexin V-fluorescein isothiocyanate (FITC; 
Santa Cruz Biotechnology, Inc., Dallas, TX) 24 h or 7 days 
after the rtPA injection in the healthy rats and 18 h after the 
NMDA ± rtPA injection in the excitotoxicity model. The 
animals were euthanized (an overdose 150 mg/kg intraperi-
toneal pentobarbital) 1 h after the annexin V-FITC injection, 
and the eyes were removed immediately and fixed for 15 min 
in 4% paraformaldehyde (PAF) at room temperature. Then 
the retinas were flatmounted, fixed in acetone at −20 °C for 
10 min, and permeabilized with PBS/0.3% Triton for 20 min. 
4',6-diamidino-2-phenylindole (DAPI) staining (1:5,000; 
Sigma-Aldrich, St. Louis, MO) was performed for 10 min. 
After rinsing with PBS, the retinas were finally flatmounted 
between a slide and a coverslip using mounting medium 
(Vectashield©, Vector Laboratories Inc., Burlingame, CA). 
They were visualized on a fluorescence microscope (BX51, 
Olympus, Rungis, France). Twelve photographs were taken 
following a cross pattern centered on the optic nerve. Annexin 
V-FITC-positive cells were counted using ImageJ software 
(Version 1.47p, National Institutes of Health, Bethesda, MD).
Quantification of living RGCs—To better discriminate 
the potentiating effect of rtPA on NMDA toxicity, living 
RGCs were counted at 18 h on flatmounted retinas of rats 
treated with NMDA± rtPA, using overnight incubation at 
4 °C with a goat-anti Brn3a (C-20) antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) 1:100 in blocking 
buffer (PBS, 2% bovine serum albumin, 2% Triton). Quan-
tification of living RGCs was also performed on the radial 
retinal sections.
Radial sections: The enucleated eyes were immediately fixed 
with a mixture of 4% paraformaldehyde and 0.5% glutaralde-
hyde in 1× PBS for 2 h at room temperature. The eyes were 
rinsed for 2 h in 1× PBS and dehydrated at room temperature 
with increasing ethanol concentrations before being incubated 
overnight at 4 °C with infiltration solution provided in the 
Leica Historesin Embedding kit (Rueil-Malmaison, France). 
Samples were embedded in resin (Leica), and 5-μm-thick 
histological sections passing through the optic nerve head 
were performed along the nasotemporal plane of the eye using 
a microtome (Leica). Sections were stuck on gelatin-coated 
slides, stained for 2 min with 1% toluidine blue solution, and 
observed with light microscopy under an Aristoplan light 
microscope (Leica) coupled with a Leica DFC480 camera. 
Photographs of the whole section were made, and the ganglion 
cell layer nuclei were then counted using ImageJ software.
Figure 3. Mixed electroretinogram showing rod- and cone-driven responses 24 h after intravitreal injection of saline solution or three 
different doses of rtPA (2.16, 0.54, and 0.27 µg in 5 µl) in healthy rats. A: Variation in the a-wave amplitudes (µV) from the preinjection 
recordings. B: Variation in the b-wave amplitude (µV) from the preinjection recordings. No statistically significant difference was observed 
between the recombinant tissue plasminogen activator (rtPA)- and vehicle-injected eyes.
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Statistical analysis: Statistical analysis was performed on 
GraphPad Prism (Version 5.0, GraphPad Software Inc., 
La Jolla, CA). Results were expressed as mean ± standard 
deviation (SD), and the non-parametric Mann–Whitney test 
was used to compare quantitative values between different 
groups. P values of less than 0.05 were considered statistically 
significant.
RESULTS
High-dose intravitreal rtPA induced ganglion cell death in 
healthy rats at 24 h: Twenty-four hours after intravitreal 
injection, no statistically significant difference in the number 
of apoptotic ganglion cells was observed between the eyes 
that received 0.54 or 0.27 µg of rtPA and the control eyes 
that received the vehicle (p = 0.36 and p = 0.20, respectively). 
However, there was a statistically significantly higher number 
of apoptotic ganglion cells in eyes that received 2.16 µg of 
rtPA compared to the control eyes (19.83±6.405 versus 
2.83±1.797 cells, p=0.025; Figure 1 and Figure 2).
The variation in the ERG amplitudes and culmination 
times induced by the rtPA injections were compared between 
each treatment group and the control group 24 h after injec-
tion. In the mixed ERG responses (cumulated cone- and 
rod-driven responses), there was no statistically significant 
difference in the a- and b-wave amplitude variations 24 h 
after injection (Figure 3). None of the tested intravitreal doses 
of rtPA (2.16, 0.54, and 0.27 µg) led to statistically significant 
changes in the culmination times of the a- or b-waves. The 
scotopic and photopic ERGs were not modified in any group 
24 h after treatment.
Absence of ongoing apoptotic process 7 days after intravit-
real rtPA in healthy rats: The same evaluations were repeated 
7 days after the intravitreal injections of rtPA or vehicle. 
The number of apoptotic RGCs did not differ between 
Figure 4. Assessment of retinal toxicity 18 h after intravitreal administration of rtPA in rat eyes under excitotoxic conditions. Animals 
received either N-methyl-D-aspartate (NMDA; 45 nmol/6 µl) + saline solution or NMDA (45 nmol/6 µl) + recombinant tissue plasminogen 
activator (rtPA; 0.27 µg/5 µl). A: Number of annexin V-positive retinal ganglion cells quantified on flatmounted retinas, showing no differ-
ence between the eyes that received NMDA + saline and the eyes that received NMDA + rtPA. B: Number of Brn3a-positive living retinal 
ganglion cells, quantified on flatmounted retinas, showing no difference between the eyes that received NMDA + saline and the eyes that 
received NMDA + rtPA. C: Number of living retinal ganglion cells, quantified on the toluidine blue–stained histologic radial retinal sections, 
as the number of cell nuclei visualized at the level of the retinal ganglion cell layer, showing no difference between the eyes that received 
NMDA + saline and the eyes that received NMDA + rtPA. D: Toluidine blue–stained retinal radial section illustrating the similar density of 
retinal ganglion cells in the eyes that received NMDA + saline (left) and the eyes that received NMDA + rtPA (right). GCL = ganglion cell 
layer, INL = inner nuclear layer, ONL = outer nuclear layer. Bar = 20 µm.
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the rtPA-treated eyes (2.16, 0.54, or 0.27 µg rtPA) and the 
vehicle-treated eyes (p = 0.70, 0.52, and 0.11, respectively). 
The mixed, scotopic, and photopic ERG responses did not 
show any statistically significant modification from baseline 
to 7 days post-injection in terms of the amplitudes or implicit 
times.
Absence of additive toxicity of 0.27 µg of intravitreal rtPA in 
an NMDA-induced excitotoxicity model at 18 h: The lowest 
clinical equivalent dose of rtPA (0.27 µg/5 µl), which was 
safe for healthy rat eyes, was selected to assess whether rtPA 
could potentiate NMDA-induced retinal damage in excito-
toxic conditions.
In the flatmounted retinas from the animals euthanized 
18 h after injection, the number of annexin-V-positive RGCs 
did not differ between the eyes that received intravitreal 
NMDA + vehicle and the eyes that received intravitreal 
NMDA + rtPA (0.27 µg; p = 0.70). To confirm these findings, 
we quantified the number of living RGCs in each group on 
the flatmounted retinas and the radial sections. The number 
of living RGCs did not differ between the two groups in the 
flatmounted retinas (p = 0.59) and radial sections (p = 0.67; 
Figure 4).
DISCUSSION
To dissolve blood collected in the subretinal space, and facili-
tate its displacement by gas tamponade, rtPA is commonly 
used off-label in the surgical management of SMH compli-
cating neovascular AMD. However, optimal doses and condi-
tions of use have not been evaluated by the manufacturer for 
intraocular administration. The reported doses in clinical 
studies vary from 10 to 100 µg/0.1 ml [9,11,13,15,16]. Retinal 
toxicity has been suspected after a single intravitreal admin-
istration of 100 µg of rtPA [11] or two injections of 50 µg at a 
48-h interval [39]. Controversially, others studies reported no 
deleterious effects with 100 µg [9,15,40] or 50 µg [13,41-43] 
of intravitreal rtPA.
In the present study, we observed that a transient increase 
in RGC death was induced in healthy rat eyes 24 h after 
intravitreal injection of the highest dose of rtPA (2.16 µg/5 µl, 
corresponding to 200 µg/0.1 ml in the human vitreous), which 
was not associated with functional modifications on ERG. 
Injection of lower doses (0.27 and 0.54 µg/5 µl) did not induce 
RGC death or changes on the ERG at any time point.
The exact mechanisms of rtPA-induced RGC toxicity 
remain uncertain. Proposed mechanisms for the retinal 
toxicity of tPA are summarized in Table 1. L-arginine, 
contained in the commercial formulation of rtPA, has been 
incriminated in the toxicity of high-dose rtPA because 
L-arginine is a substrate for nitric oxide (NO) synthases. 
Different types of NO synthases are present in RGCs and 
photoreceptors [44,45], and NO produced by the inducible or 
constitutive form of NO synthases could exert toxic effects. 
Activation of the NR1 subunit of the NMDAR by rtPA could 
enhance calcium influx into the cell [21-23] and subsequently 
accelerate neuronal cell death, as shown to occur in the brain. 
In the present experiments, the variations in the ERG signals 
did not statistically significantly differ between the treatment 
and control groups because the proportion of damaged cells 
necessary to alter responses to full-field ERG might not have 
been reached. This also suggests that retinal toxicity might 
be overlooked in the clinical setting. In healthy rats, doses 
of 0.27 and 0.54 µg/5 µl, equivalent to 25 and 50 µg/0.1 ml 
in the human vitreous, did not exert retinal toxicity. These 
results are in accordance with previous studies performed 
in other animal models, such as cats and rabbits. Harach et 
al. observed fundus pigmentary alterations in cat eyes that 
received intravitreal doses ≥50 µg/0.1 ml. On electroretinog-
raphy, the scotopic b-wave amplitudes were reduced 14 days 
after treatment with doses ≥50 µg/0.1 ml, while the a-wave 
amplitudes were reduced with doses ≥75 µg/0.1 ml [29]. In 
rabbit eyes, Johnson et al. found no evidence of retinal toxic 
reaction in eyes that received 25 µg/0.1 ml of intravitreal rtPA 
[30]. Similarly, Rowley et al. did not observe retinal toxicity at 
increasing doses up to 50 µg/0.1 ml. However, with doses of 
200 µg/0.1 ml or more, there was evidence of retinal toxicity 
on electroretinography, ophthalmoscopy, and histology [28].
Clinically, rtPA is administered in eyes with advanced, 
uncontrolled, or refractory neovascular AMD complicated 
by SMH. In these severely affected eyes, retinal neurons and 
supportive cells are submitted to an intense, multifactorial 
cellular stress. As enhanced rtPA toxicity has been reported 
in the brain submitted to excitotoxic stress, we also evalu-
ated the retinal toxicity of intravitreal rtPA, in excitotoxic 
conditions. We used two quantitative methods to assess 
RGC apoptosis and survival on flatmounted and sectioned 
retinas. In this experimental setting, we did not observe any 
potentiating neurotoxic effect of the low clinical equivalent 
dose of rtPA. Although this finding could be related to the 
low dose used, and should be confirmed with other doses 
and other routes of administration, it is consistent with the 
reported paradoxical neuroprotective effect of low-dose tPA 
in excitotoxic conditions [25].
In summary, these results confirm that human equiva-
lent doses of rtPA injected into the vitreous (corresponding 
to 25–50 µg/0.1 ml in the human eye) are safe for the retina. 
The lowest dose (corresponding to 25 µg/0.1 ml) does not 
potentiate the neurotoxicity of excitotoxic conditions. This 
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finding carries statistically significant clinical implications as 
it indicates that this dose can be used safely in patients with 
submacular hemorrhage due to AMD or other retinal vascular 
disorders, and those with frequently associated neurodegen-
erative diseases, such as glaucoma.
APPENDIX 1.
To access the data, click or select the words “Appendix 1.”
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